HHS Announces Draft Enforcement Discretion Policy Paving Way for Pharmacies to Compound Certain Peptides While FDA Rulemaking Is Pending
On October 28, 2026, the U.S. Department of Health and Human Services (HHS) announced a draft policy under which it does not intend to take enforcement action against a…
DO
By Daniel Okafor · Regulatory Correspondent
Nov 2 16:38 ETSource: Arnold & Porter
From the source
Read at arnoldporter.comHHS Announces Draft Enforcement Discretion Policy Paving Way for Pharmacies to Compound Certain Peptides While FDA Rulemaking Is Pending
On October 28, 2026, the U.S. Department of Health and Human Services (HHS) announced a draft policy under which it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds a drug using one of six peptide bulk drug substances (BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500) when 10 conditions are met. 1 The policy appli
